Iovance Biotherapeutics, Inc. IOVA Gross margin
Gross margin at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s gross margin?
- Iovance Biotherapeutics, Inc. (IOVA) reported gross margin of 36.7% in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s gross margin changed year-over-year?
- Iovance Biotherapeutics, Inc.'s gross margin increased by 12.7% year-over-year, from 32.6% to 36.7%.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s gross margin?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s gross margin has grown at a 54.5% compound annual growth rate (CAGR), from 13.1% to 31.3%.
- What does gross margin mean?
- Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.